Tapentadol IR (CG5503) + Placebo + Oxycodone HCL IR + Tapentadol IR (CG5503)
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Arthroplasty
Conditions
Arthroplasty
Trial Timeline
Oct 1, 2006 → Dec 1, 2007
NCT ID
NCT00364533About Tapentadol IR (CG5503) + Placebo + Oxycodone HCL IR + Tapentadol IR (CG5503)
Tapentadol IR (CG5503) + Placebo + Oxycodone HCL IR + Tapentadol IR (CG5503) is a phase 3 stage product being developed by Johnson & Johnson for Arthroplasty. The current trial status is terminated. This product is registered under clinical trial identifier NCT00364533. Target conditions include Arthroplasty.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00364533 | Phase 3 | Terminated |
Competing Products
9 competing products in Arthroplasty
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DU-176b | Daiichi Sankyo | Phase 2 | 52 |
| YM150 + Warfarin | Astellas Pharma | Phase 2 | 52 |
| Zoledronic acid 5mg | Novartis | Approved | 85 |
| Denosumab | Amgen | Phase 2 | 51 |
| JNJ-70033093 25 mg + JNJ-70033093 50 mg + JNJ-70033093 100 mg + JNJ-70033093 200 mg + Placebo + Enoxaparin 40 mg | Bristol Myers Squibb | Phase 2 | 51 |
| Enoxaparin sodium | Sanofi | Phase 3 | 76 |
| 48-hour ropivacaine infusions + Single dose ropivacaine + Patient controlled analgesics | Sanofi | Pre-clinical | 22 |
| Enoxaparin + Apixaban + BAY1213790 | Bayer | Phase 2 | 49 |
| Rivaroxaban (Xarelto, BAY59-7939) | Bayer | Pre-clinical | 20 |